Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006042 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00006042: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00006042 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006042, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of cyclophosphamide plus bone marrow transplantation in treating patients who have hematologic cancer.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- DRUG tacrolimus
- BIOLOGICAL filgrastim
- DRUG mycophenolate mofetil
Study Locations (1)
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Phase | Phase 1 |
What the finished NCT00006042 record still lists
NCT00006042 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00006042 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00006042 about?
NCT00006042 is a clinical study titled "Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase I trial to stud...
What is the current status of trial NCT00006042?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-12.
What conditions does trial NCT00006042 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases.
What interventions are being tested in trial NCT00006042?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), tacrolimus (DRUG), filgrastim (BIOLOGICAL), mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00006042?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006042 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia